Andrew Reardon
General Counsel at Ligand Pharmaceuticals Inc (LGND)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $10.3M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 83336,021 held (−2%) | $302.51 | $252K | -0.2% |
| Oct 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,97634,045 held (−5%) | $303.54 | $600K | -0.6% |
| Oct 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,53532,510 held (−5%) | $304.52 | $467K | -0.9% |
| Oct 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 40432,106 held (−1%) | $306.18 | $124K | -1.4% |
| Oct 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 23531,871 held (−1%) | $307.19 | $72K | -1.8% |
| Oct 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1731,854 held (−0%) | $307.74 | $5K | -1.9% |
| Sep 8SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 30041,214 held (−1%) | $283.99 | $85K | +6.3% |
| Sep 8SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,80039,414 held (−4%) | $285.17 | $513K | +5.8% |
| Sep 8SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 2,11537,299 held (−5%) | $286.36 | $606K | +5.4% |
| Sep 8SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 38536,914 held (−1%) | $287.53 | $111K | +5.0% |
| Sep 8SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 40036,514 held (−1%) | $288.98 | $116K | +4.4% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 10546,409 held (−0%) | $284.14 | $30K | +6.2% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 3346,376 held (−0%) | $284.55 | $9K | +6.1% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 15746,219 held (−0%) | $285.74 | $45K | +5.6% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,03245,187 held (−2%) | $286.80 | $296K | +5.2% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,21443,973 held (−3%) | $287.77 | $349K | +4.9% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 35643,617 held (−1%) | $288.75 | $103K | +4.5% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 50343,114 held (−1%) | $289.80 | $146K | +4.1% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 20042,914 held (−0%) | $290.60 | $58K | +3.9% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 99141,923 held (−2%) | $291.71 | $289K | +3.5% |
| Aug 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 40941,514 held (−1%) | $292.82 | $120K | +3.1% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 39646,118 held (−1%) | $308.99 | $122K | -2.3% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 10446,014 held (−0%) | $310.20 | $32K | -2.7% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,11944,895 held (−2%) | $311.72 | $349K | -3.2% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,08143,814 held (−2%) | $312.28 | $338K | -3.4% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 70043,114 held (−2%) | $313.46 | $219K | -3.7% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 10043,014 held (−0%) | $314.58 | $31K | -4.1% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 90042,114 held (−2%) | $315.78 | $284K | -4.4% |
| Jul 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 60041,514 held (−1%) | $317.15 | $190K | -4.8% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 49145,891 held (−1%) | $223.95 | $110K | +34.8% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 67745,214 held (−1%) | $225.20 | $152K | +34.0% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,43243,782 held (−3%) | $225.97 | $324K | +33.6% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 40043,382 held (−1%) | $226.78 | $91K | +33.1% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 58442,798 held (−1%) | $228.57 | $133K | +32.0% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,21641,582 held (−3%) | $229.47 | $279K | +31.5% |
| Jun 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 20041,382 held (−0%) | $230.41 | $46K | +31.0% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 60045,782 held (−1%) | $227.45 | $136K | +32.7% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 93244,850 held (−2%) | $228.75 | $213K | +31.9% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 9844,752 held (−0%) | $229.71 | $23K | +31.4% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 37044,382 held (−1%) | $230.87 | $85K | +30.7% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 78043,602 held (−2%) | $232.04 | $181K | +30.1% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,42042,182 held (−3%) | $232.92 | $331K | +29.6% |
| May 4SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 80041,382 held (−2%) | $234.02 | $187K | +29.0% |
| Apr 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 46045,922 held (−1%) | $198.85 | $91K | +51.8% |
| Apr 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,30244,620 held (−3%) | $199.72 | $260K | +51.1% |
| Apr 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,23843,382 held (−3%) | $200.94 | $249K | +50.2% |
| Apr 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 70042,682 held (−2%) | $201.90 | $141K | +49.5% |
| Apr 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 96341,719 held (−2%) | $203.22 | $196K | +48.5% |
| Apr 2SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 33741,382 held (−1%) | $204.50 | $69K | +47.6% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 10041,769 held (−0%) | $197.70 | $20K | +52.7% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 10041,669 held (−0%) | $199.01 | $20K | +51.7% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 20741,462 held (−0%) | $199.96 | $41K | +50.9% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 9341,369 held (−0%) | $200.62 | $19K | +50.4% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 30041,069 held (−1%) | $201.70 | $61K | +49.6% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 20040,869 held (−0%) | $204.17 | $41K | +47.8% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 46040,409 held (−1%) | $205.18 | $94K | +47.1% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 34040,069 held (−1%) | $206.37 | $70K | +46.2% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 61239,457 held (−2%) | $207.01 | $127K | +45.8% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,44638,011 held (−4%) | $208.12 | $301K | +45.0% |
| Mar 6SEC | LGNDLigand Pharmaceuticals Inc | Sell Plan | 1,14236,869 held (−3%) | $208.87 | $239K | +44.5% |
- Sell
General Counsel Andrew Reardon sold $252K of LGND at $302.51 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Andrew Reardon sold $600K of LGND at $303.54 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Andrew Reardon sold $467K of LGND at $304.52 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Andrew Reardon sold $124K of LGND at $306.18 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Andrew Reardon sold $72K of LGND at $307.19 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Andrew Reardon sold $5K of LGND at $307.74 — pre-scheduled 10b5-1 plan sale.